Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that MET Exon 14 (Splice Site) status confers therapeutic sensitivity to Tepotinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
TEPMETKO (tepotinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.